BACKGROUND: HER-2/neu overexpression plays a critical role in breast cancer development, and its expression in ductal carcinoma in situ (DCIS) is associated with development of invasive breast cancer. A vaccine targeting HER-2/neu expression in DCIS may initiate immunity against invasive cancer. METHODS: A HER-2/neu dendritic cell vaccine was administered to 27 patients with HER-2/neu-overexpressing DCIS. The HER-2/neu vaccine was administered before surgical resection, and pre- and postvaccination analysis was conducted to assess clinical results. RESULTS: At surgery, 5 of 27 (18.5%) vaccinated subjects had no evidence of remaining disease, whereas among 22 subjects with residual DCIS, HER-2/neu expression was eradicated in 11 (50%). When comparing estrogen receptor (ER)(neg) with ER(pos) DCIS lesions, vaccination was more effective in hormone-independent DCIS. After vaccination, no residual DCIS was found in 40% of ER(neg) subjects compared with 5.9% in ER(pos) subjects. Sustained HER-2/neu expression was found in 10% of ER(neg) subjects compared with 47.1% in ER(pos) subjects (P = .04). Postvaccination phenotypes were significantly different between ER(pos) and ER(neg) subjects (P = .01), with 7 of 16 (43.8%) initially presenting with ER(pos) HER-2/neu(pos) luminal B phenotype finishing with the ER(pos) HER-2/neu(neg) luminal A phenotype, and 3 of 6 (50%) with the ER(neg) HER-2/neu(pos) phenotype changing to the ER(neg) HER-2/neu(neg) phenotype. CONCLUSIONS: Results suggest that vaccination against HER-2/neu is safe and well tolerated and induces decline and/or eradication of HER-2/neu expression. These findings warrant further exploration of HER-2/neu vaccination in estrogen-independent breast cancer and highlight the need to target additional tumor-associated antigens and pathways.
BACKGROUND:HER-2/neu overexpression plays a critical role in breast cancer development, and its expression in ductal carcinoma in situ (DCIS) is associated with development of invasive breast cancer. A vaccine targeting HER-2/neu expression in DCIS may initiate immunity against invasive cancer. METHODS: A HER-2/neu dendritic cell vaccine was administered to 27 patients with HER-2/neu-overexpressing DCIS. The HER-2/neu vaccine was administered before surgical resection, and pre- and postvaccination analysis was conducted to assess clinical results. RESULTS: At surgery, 5 of 27 (18.5%) vaccinated subjects had no evidence of remaining disease, whereas among 22 subjects with residual DCIS, HER-2/neu expression was eradicated in 11 (50%). When comparing estrogen receptor (ER)(neg) with ER(pos) DCIS lesions, vaccination was more effective in hormone-independent DCIS. After vaccination, no residual DCIS was found in 40% of ER(neg) subjects compared with 5.9% in ER(pos) subjects. Sustained HER-2/neu expression was found in 10% of ER(neg) subjects compared with 47.1% in ER(pos) subjects (P = .04). Postvaccination phenotypes were significantly different between ER(pos) and ER(neg) subjects (P = .01), with 7 of 16 (43.8%) initially presenting with ER(pos) HER-2/neu(pos) luminal B phenotype finishing with the ER(pos) HER-2/neu(neg) luminal A phenotype, and 3 of 6 (50%) with the ER(neg) HER-2/neu(pos) phenotype changing to the ER(neg) HER-2/neu(neg) phenotype. CONCLUSIONS: Results suggest that vaccination against HER-2/neu is safe and well tolerated and induces decline and/or eradication of HER-2/neu expression. These findings warrant further exploration of HER-2/neu vaccination in estrogen-independent breast cancer and highlight the need to target additional tumor-associated antigens and pathways.
Authors: Shuwen Xu; Gary K Koski; Mark Faries; Isabelle Bedrosian; Rosemarie Mick; Markus Maeurer; Martin A Cheever; Peter A Cohen; Brian J Czerniecki Journal: J Immunol Date: 2003-09-01 Impact factor: 5.422
Authors: Sonia A Perez; Panagiota A Sotiropoulou; Nectaria N Sotiriadou; Avgi Mamalaki; Angelos D Gritzapis; Hartmut Echner; Wolfgang Voelter; Graham Pawelec; Michael Papamichail; Constantin N Baxevanis Journal: Cancer Immunol Immunother Date: 2001-11-23 Impact factor: 6.968
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: James L Murray; Michael E Gillogly; Donna Przepiorka; Hannah Brewer; Nuhad K Ibrahim; Daniel J Booser; Gabriel N Hortobagyi; Andrzej P Kudelka; Kenneth H Grabstein; Martin A Cheever; Constantin G Ioannides Journal: Clin Cancer Res Date: 2002-11 Impact factor: 12.531
Authors: Vessela N Kristensen; Charles J Vaske; Josie Ursini-Siegel; Peter Van Loo; Silje H Nordgard; Ravi Sachidanandam; Therese Sørlie; Fredrik Wärnberg; Vilde D Haakensen; Åslaug Helland; Bjørn Naume; Charles M Perou; David Haussler; Olga G Troyanskaya; Anne-Lise Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2011-09-09 Impact factor: 11.205
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Isabelle Bedrosian; Rosemarie Mick; Shuwen Xu; Harvey Nisenbaum; Mark Faries; Paul Zhang; Peter A Cohen; Gary Koski; Brian J Czerniecki Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Jashodeep Datta; Cinthia Rosemblit; Erik Berk; Lori Showalter; Prachi Namjoshi; Rosemarie Mick; Kathreen P Lee; Andrew M Brod; Rachel L Yang; Rachel R Kelz; Elizabeth Fitzpatrick; Clifford Hoyt; Michael D Feldman; Paul J Zhang; Shuwen Xu; Gary K Koski; Brian J Czerniecki Journal: Oncoimmunology Date: 2015-04-01 Impact factor: 8.110
Authors: Florian Schütz; Frederik Marmé; Christoph Domschke; Christof Sohn; Alexandra von Au Journal: Breast Care (Basel) Date: 2018-01-31 Impact factor: 2.860
Authors: Keith L Knutson; Raphael Clynes; Barath Shreeder; Patrick Yeramian; Kathleen P Kemp; Karla Ballman; Kathleen S Tenner; Courtney L Erskine; Nadine Norton; Donald Northfelt; Winston Tan; Carmen Calfa; Mark Pegram; Elizabeth A Mittendorf; Edith A Perez Journal: Cancer Res Date: 2016-04-20 Impact factor: 12.701